Integrated serum metabolomics reveal molecular mechanism of Xietu Hemu prescription on metabolic dysfunction-associated steatotic liver disease-related obesity

Figure 7 Xietu Hemu prescription inhibits lipid synthesis of mature 3T3-L1 cells through the leptin signal axis at the protein level of the nucleus and cytoplasm. A: Secretion levels of leptin (LEP) at different time points during high dose of Xietu Hemu prescription (XHP) intervention in 3T3-L1 cell differentiation; B: Immunofluorescence assay for protein expression of LEP after 10 days of XHP intervention in 3T3-L1 cell differentiation at different concentrations; C-H: Detection and quantitative statistics of cytoplasm protein levels on day 10 (n = 3); I-K: Detection and quantitative statistics of nucleus protein levels on day 10 (n = 3). Data were expressed as mean ± SEM. 200 ×, 50 μm; 400 ×, 25 μm; ^aP < 0.05 vs control; ^bP < 0.01 vs control; ^cP < 0.005 vs control; ^dP < 0.001 vs control; ^eP < 0.05 vs model; ^fP < 0.01 vs model; ^gP < 0.005 vs model; ^hP < 0.001 vs model; ⁱP < 0.05 vs low dose of XHP (L-XHP); ^jP < 0.001 vs L-XHP; ^kP < 0.001 vs medium dose of XHP. L-XHP: Low dose of Xietu Hemu prescription; M-XHP: Medium dose of Xietu Hemu prescription; H-XHP: High dose of Xietu Hemu prescription; LEP: Leptin.